Enliven Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Enliven Therapeutics Depreciation & Amortization Growth & History (ELVN)
Enliven Therapeutics's depreciation and amortization was $300,000 for fiscal 2025.
View full Enliven Therapeutics company overviewEnliven Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $300,000 | $0 | 0.00% |
| 2024 | 2024-12-31 | $300,000 | $0 | 0.00% |
| 2023 | 2023-12-31 | $300,000 | $100,000 | +50.00% |
| 2022 | 2022-12-31 | $200,000 | $101,000 | +102.02% |
| 2021 | 2021-12-31 | $99,000 | $2,000 | +2.06% |
| 2020 | 2020-12-31 | $97,000 | $64,000 | +193.94% |
| 2019 | 2019-12-31 | $33,000 | — | — |
Enliven Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7,000 | −$74,000 | −91.36% |
| Q1 2026 | 2026-03-31 | $14,000 | −$60,000 | −81.08% |
| Q4 2025 | 2025-12-31 | $46,000 | — | — |
| Q3 2025 | 2025-09-30 | $62,000 | −$18,000 | −22.50% |
| Q2 2025 | 2025-06-30 | $81,000 | $2,000 | +2.53% |
| Q1 2025 | 2025-03-31 | $74,000 | −$5,000 | −6.33% |
| Q3 2024 | 2024-09-30 | $80,000 | $1,000 | +1.27% |
| Q2 2024 | 2024-06-30 | $79,000 | $5,000 | +6.76% |
| Q1 2024 | 2024-03-31 | $79,000 | −$66.9M | −99.88% |
| Q3 2023 | 2023-09-30 | $79,000 | $19,000 | +31.67% |
| Q2 2023 | 2023-06-30 | $74,000 | $22,000 | +42.31% |
| Q1 2023 | 2023-03-31 | $67.0M | $28.0M | +71.79% |
| Q3 2022 | 2022-09-30 | $60,000 | $36,000 | +150.00% |
| Q2 2022 | 2022-06-30 | $52,000 | $27,000 | +108.00% |
| Q1 2022 | 2022-03-31 | $39.0M | $39.0M | +155900.00% |
| Q3 2021 | 2021-09-30 | $24,000 | −$1,000 | −4.00% |
| Q2 2021 | 2021-06-30 | $25,000 | $0 | 0.00% |
| Q1 2021 | 2021-03-31 | $25,000 | $1,000 | +4.17% |
| Q3 2020 | 2020-09-30 | $25,000 | — | — |
| Q2 2020 | 2020-06-30 | $25,000 | — | — |
| Q1 2020 | 2020-03-31 | $24,000 | — | — |
Enliven Therapeutics depreciation and amortization trends
Over the last five fiscal years, Enliven Therapeutics's depreciation and amortization increased from $97,000 to $300,000, a change of $203,000. The latest reported quarter, Q2 2026, shows $7,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enliven Therapeutics source filings ↗